VA-DXC-TECHNOLOGY
15.1.2019 15:02:11 CET | Business Wire | Press release
A vast majority of businesses will increase their investments in digital technology over the coming year, and many expect IT modernization to fuel future transformation efforts that lead to cost savings and greater profitability. These are some of the findings from a new global survey conducted by The Economist Intelligence Unit (EIU) and commissioned by DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company.
The study, “2019: The Year of Digital Decisions ,” explores how companies define digital transformation and the resulting business outcomes. Significantly, the report reveals that more than eight in ten survey respondents (83 percent) expect their organizations to increase their digital investments in 2019. And more than 40 percent of respondents predict that their organizations will increase their investments by 11 percent or more.
Currently, approximately half of companies surveyed have digitally enabled just three key organizational functions, according to the research. When asked to cite the top barriers to transformation, more than one-third (35 percent) of respondents flagged “cost or lack of funding,” second only to security concerns (40 percent).
However, most companies surveyed (76 percent) expect the cost savings from IT services modernization to help fund their digital strategy. Within the next three years, companies intend to greatly ramp up their efforts, and more than half of respondents (58 percent) expect every business unit to be digitally enabled in the next three years.
“Companies overwhelmingly recognize that digital innovation is now a requirement for them to compete and succeed,” said Dan Hushon , senior vice president and chief technology officer, DXC Technology. “The survey findings point to perhaps the most rapid, dramatic and sophisticated effort at reinvention that major businesses have attempted in many decades, and those surveyed are committed to investing to make digital happen.”
Survey respondents also linked digital transformation to profits. More than two-thirds (68 percent) say the annual profitability of their organizations has increased over the past three years thanks to their organizations’ digital strategy, and 74 percent say they expect it to rise over the next three years.
“We strongly believe that we can make the customer experience easier and simpler while leading to better outcomes through digital technology, and that will continue to drive our market share,” said survey report interviewee Neesha Hathi, executive vice president and chief digital officer at Charles Schwab. “Digital transformation also helps us scale our services while driving down costs for our clients.”
Digital decision drivers
The report reveals what companies aim to achieve by digitally remaking themselves, as well as the challenges they must overcome and the cultural changes they need to make. Other key findings include:
- Digital and business strategy formulation are completely or almost completely aligned at 72 percent of companies.
- Three-fourths (75 percent) of respondents say digital transformation will lead to greater agility, and 76 percent report that modern digital IT infrastructures better position their companies to produce value for their stakeholders.
- Approximately one-third (33 percent) of respondents say the lack of a tech-savvy workforce is a barrier to transformation.
- Nearly three-fourths (72 percent) of companies agree that a change in culture is necessary to digitally transform any organization. That figure is even higher for companies in developing regions and those that have implemented digital strategies only in the past two years.
“Our research indicates that digital strategy will continue to be a major area of investment – amounting to a dramatic effort at corporate reinvention. But getting it right will be a continuing challenge,” said Gilda Stahl, managing editor, thought leadership, at The Economist Intelligence Unit. “Defining your digital strategy clearly, ensuring digital literacy in every relevant role and recruiting digital-savvy employees are all essential to guaranteeing that digital investment yields positive business outcomes.”
Key regional and industry trends
- Companies that are further advanced – for example, those headquartered in North America and Europe and those in the financial services and manufacturing industries – tend to place greater emphasis on cross-functional collaboration, possibly because this helps them to optimize the digital investments they’ve already made.
- Financial services companies are more likely to stress AI/machine learning and blockchain while, for manufacturing companies, cloud computing and IoT are especially important.
- Social media is a somewhat higher priority for retailers than for other industries, given the importance to them of developing digital channels for sales and marketing. These tools play a growing role at marketing and communications firms as well.
Methodology
The Economist Intelligence Unit surveyed 621 senior executives in September and October 2018 to discover where companies are in their digital development and what they want to achieve with digital transformation. Respondents were members of the C-suite or held other senior leadership roles, including executive vice presidents, managing directors, and directors. Companies surveyed ranged in size from US$500 million to US$5 billion or more in annual revenue. Respondents were widely distributed across functions and industries — healthcare, manufacturing, retail and insurance are the biggest sectors represented.
Resources:
- 2019: The Year of Digital Decisions report
- Infographic: “Fostering an enterprise digital culture”
- Blog post: “Survey: Companies poised to go all-in on digital transformation in 2019”
- Follow DXC Technology on Twitter: https://twitter.com/DXCTechnology
- Join the conversation: #DXCDigitalDirections
About DXC Technology
As the world's leading independent, end-to-end IT services company, DXC Technology (NYSE: DXC) leads digital transformations for clients by modernizing and integrating their mainstream IT, and by deploying digital solutions at scale to produce better business outcomes. The company’s technology independence, global talent, and extensive partner network enable 6,000 private and public-sector clients in 70 countries to thrive on change. DXC is a recognized leader in corporate responsibility. For more information, visit dxc.technology and explore THRIVE , DXC’s digital destination for changemakers and innovators.
About The Economist Intelligence Unit
The Economist Intelligence Unit (EIU) is the research and analysis division of The Economist Group, the sister company to The Economist newspaper. Created in 1946, EIU has nearly 70 years’ experience in helping businesses, financial firms and governments to understand how the world is changing and how that creates opportunities to be seized and risks to be managed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005239/en/
Contact:
Allison Wilson, Corporate Media Relations +1.352.502.9539, dwilson215@dxc.com
Donna Jenks, Corporate Media Relations +1.630.306.9989, donna.jenks@dxc.com
Jonathan Ford, Investor Relations +1.703.245.9700, jonathan.ford@dxc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
